Angiogenesis has been identified as a relevant target for melanoma experimental therapeutics, based on preclinical and clinical studies. A variety of angiogenesis inhibitors are currently being tested in both metastatic and adjuvant melanoma clinical trials. To date, the most promising evidence of benefit is based on a statistically nonsignificant trend in survival gain reported in a randomized phase II trial combining bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, with cytotoxic chemotherapy. Larger phase III studies are required to determine the true extent of clinical benefit with this class of agents. Key to these clinical trials is the need to include translational endpoints, since correlation of biological and clinical data will provide the opportunity to identify biomarkers predictive of treatment response. These biological studies will also aid our, as yet, poor understanding of the mechanism of action of angiogenesis inhibitors, as well as drug-related side effects. Finally, if these trials show meaningful clinical benefit, then careful consideration will need to be given when designing second-generation trials, in the light of novel gene-directed therapies currently showing promise in melanoma.
Amaravadi, R.K., Schuchter, L.M., McDermott, D.F., Kramer, A., Giles, L., Gramlich, K. et al. (2009) Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res15: 7711-7718.
2.
Basu, B., Biswas, S., Wrigley, J., Sirohi, B. and Corrie, P.(2009) Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. Expert Rev Anticancer Ther9: 1583-1598.
3.
Boasberg, P., Cruickshank, S., Hamid, O., O’Day, S., Weber, R. and Spitler, L. ( 2009) Nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable stage III and IV melanoma. J Clin Oncol27: Abstract 9061.
4.
Brooks, P.C., Montgomery, A.M., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier, G. et al. (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell79: 1157-1164.
5.
Chirivi, R.G., Garofalo, A., Crimmin, M.J., Bawden, L.J., Stoppacciaro, A., Brown, P.D. et al. (1994) Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor . Int J Cancer58: 460-464.
6.
Cook, N., Basu, B., Biswas, S., Kareclas, P., Mann, C., Palmer, C. et al. (2010) A phase 2 study of vatalanib in metastatic melanoma patients. Eur J Cancer (in press).
7.
Corrie, P., Marshall, A., East, C., Dunn, J., Ahern, A., Lorigan, P. et al. (2009) Safety of adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence. In 7th World Congress on Melanoma, Abstract p237.
8.
Cui, C., Chi, Z., Yuan, X., Si, L., Sheng, X., Shen, L. et al. (2009) Endostatin combined with chemotherapy as first-line therapy for stage IV melanoma patients: A phase II clinical study. J Clin Oncol27: Abstract e20003.
9.
Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S. et al. (2002) Mutations of the BRAF gene in human cancer . Nature417: 949-954.
10.
Decoster, L., Broek, I.V., Declerq, D., Anckaert, E., Majois, F., Baurain, J.F. et al. (2009) Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers. Eur J Cancer Suppl7: 577-578.
11.
Eisen, T., Ahmad, T., Flaherty, K.T., Gore, M., Kaye, S., Marais, R. et al. (2006) Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer95: 581-586.
12.
Eisen, T., Marais, R., Affolter, A., Lorigan, P., Ottensmeier, C., Robert, C., et al. (2007) An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma. J Clin Oncol25: Abstract 8529.
13.
Ellis, L.M. and Hicklin, D.J. ( 2008) VEGF-targeted therapy: mechanisms of anti-tumour activity . Nat Rev Cancer8: 579-591.
14.
Ferrara, N., Gerber, H.P. and LeCouter, J. ( 2003) The biology of VEGF and its receptors. Nat Med9: 669-676.
15.
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L. et al. (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell131: 463-475.
16.
Folkman, J. ( 1971) Tumor angiogenesis: therapeutic implications. N Engl J Med285: 1182-1186.
17.
Fruehauf, J., Lutzky, J., McDermott, D., Brown, C., Pithavala, Y., Bycott, P. et al. (2008) Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study. J Clin Oncol26: Abstract 9006.
18.
González-Cao, M., Viteri, S., Díaz-Lagares, A., González, A., Redondo, P., Nieto, Y. et al. (2008) Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology74: 12-16.
19.
Goydos, J.S. and Gorski, D.H. ( 2003) Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma. Clin Cancer Res9: 5962-5967.
20.
Graells, J., Vinyals, A., Figueras, A., Llorens, A., Moreno, A., Marcoval, J. et al. (2004) Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol123: 1151-1161.
21.
Gutheil, J.C., Campbell, T.N., Pierce, P.R., Watkins, J.D., Huse, W.D., Bodkin, D.J. et al. (2000) Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3 . Clin Cancer Res6: 3056-3061.
22.
Hanahan, D. and Bergers, G. ( 2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer8: 592-603.
23.
Hanahan, D. and Folkman, J. ( 1996) Patterns and emerging mechanisms of the angiogeneic switch during tumorigenesis. Cell86: 353-364.
24.
Hanahan, D. and Weinberg, R.A. ( 2000) The hallmarks of cancer. Cell100: 57-70.
25.
Hauschild, A., Agarwala, S.S., Trefzer, U., Hogg, D., Robert, C., Hersey, P. et al. (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol27: 2823-2830.
26.
Hewitson, K.S. and Schofield, C.J. ( 2004) The HIF pathway as a therapeutic target. Drug Discov Today9: 704-711.
27.
Holash, J., Davis, S., Papadopoulos, N., Croll, S.D., Ho, L., Russell, M. et al. (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA99: 11393-11398.
28.
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med350: 2335-2342.
29.
Indraccolo, S. ( 2010) Interferon-alpha as angiogenesis inhibitor: learning from tumour models. Autoimmunity43: 244-247.
30.
Jain, R.K. ( 2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med7: 987-989.
31.
Kim, K., Diwan, A., Papadopoulos, N., Bedikian, A., Camacho, L., Hwu, P. et al. (2007) A randomized phase II study of EMD 121974 in patients (pts) with metastatic melanoma (MM). J Clin Oncol25: 8548.
32.
Kim, K., Saro, J., Moschos, S., Hwu, P., Tarhini, A., Hwu, W. et al. (2008) A phase I dose finding and biomarker study of TKI258 (dovitinib lactate) in patients with advanced melanoma. J Clin Oncol26: Abstract v9026.
33.
Kim, K.B., Davies, M.A., Papadopoulos, N.E., Bedidian, A.Y., Hwu, W., Woodward, K. et al. (2009) Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. J Clin Oncol27: Abstract 9026.
34.
Kuenen, B.C., Tabernero, J., Baselga, J., Cavalli, F., Pfanner, E., Conte, P.F. et al. (2003) Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res9: 1648-1655.
35.
Kuwada, S.K. ( 2007) Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. Curr Opin Mol Ther9: 92-98.
36.
Li, Y., Wang, M.N., Li, H., King, K.D., Bassi, R., Sun, H. et al. (2002) Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med195: 1575-1584.
37.
Ling, Y., Yang, Y., Lu, N., You, Q.D., Wang, S., Gao, Y. et al. (2007) Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun361: 79-84.
38.
Loquai, C., Pavlick, A., Lawson, D., Gutzmer, R., Richards, J., Gore, M.E. et al. (2009) Randomized phase II study of the safety and efficacy of a human anti-αv integrin monoclonal antibody (CNTO 95) alone and in combination with dacarbazine in patients with stage IV metastatic melanoma: 12-month results. J Clin Oncol27: Abstract 9029.
39.
Mahabeshwar, G.H. and Byzova, T.V. ( 2007) Angiogenesis in melanoma. Semin Oncol34: 555-565.
40.
McDermott, D.F., Sosman, J.A., Gonzalez, R., Hodi, F.S., Linette, G.P., Richards, J. et al. (2008) Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol26: 2178-2185.
41.
Mehnert, J., McCarthy, M., Aziz, S., Sznol, M., Flaherty, K., Camp, R. et al. (2007) VEGF, VEGFR1 and VEGFR2 expression in melanoma . J Clin Oncol25: Abstract 8520.
42.
Menakuru, S.R., Brown, N.J., Staton, C.A. and Reed, M.W.R. ( 2008) Angiogenesis in pre-malignant conditions. Br J Cancer99: 1961-1966.
43.
Mouawad, R., Spano, J.P., Comperat, E., Capron, F. and Khayat, D. ( 2009) Tumoural expression and circulating level of VEGFR-3 (Flt-4) in meta
44.
static melanoma patients: correlation with clinical parameters and outcome . Eur J Cancer45: 1407-1414.
45.
Munzone, E., Testori, A., Minchella, I., Mosconi, C., Passoni, E., Verri, M. et al. (2007) A phase II trial of dacarbazine (DTIC) and bevacizumab in patients with metastatic melanoma. J Clin Oncol25: Abstract 8579.
46.
Murukesh, N., Dive, C. and Jayson, G.C.(2010) Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer102: 8-18.
47.
O’Day, S., Kim, K.J., Sosman, A., Peterson, A., Feng, S., Minor, D. et al. (2009) A randomized phase II study evaluating the activity of Bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated Advanced Melanoma. Eur J Cancer Suppl7: Abstract 23LBA.
48.
Oku, T., Tjuvajev, J.G., Miyagawa, T., Sasajima, T., Joshi, A., Joshi, R. et al. (1998) Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res58: 4185-4192.
49.
Osella-Abate, S., Quaglino, P., Savoia, P., Leporati, C., Comessatti, A. and Bernengo, M.G. ( 2002) VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res12: 325-334.
50.
Palavalli, L.H., Prickett, T.D., Wunderlich, J.R., Wei, X., Burrell, A.S., Porter-Gill, P. et al. (2009) Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet41: 518-520.
51.
Patnaik, A., Chiorean, E., Tolcher, A., Papadopoulos, K., Beeram, M., Kee, D. et al. (2009) EZN-2968, a novel hypoxia-inducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) antagonist: Results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies. J Clin Oncol27: Abstract 2564.
52.
Pavlaki, M. and Zucker, S. ( 2003) Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev22: 177-203.
53.
Perez, D.G., Suman, V.J., Fitch, T.R., Amatruda, T., Morton, R.F., Jilani, S.Z. et al. (2009) Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer115: 119-127.
54.
Peyton, J.D., Spigel, D.R., Burris, H.A., Lane, C., Rubin, M., Browning, M. et al. (2009) Phase II trial of bevacizumab and everolimus in the treatment of patients with metastatic melanoma: preliminary results . J Clin Oncol27: Abstract 9027.
55.
Poon, R.T., Fan, S. and Wong, J. ( 2001) Clinical implications of circulating angiogeneic factors in cancer patients. J Clin Oncol19: 1207-1225.
56.
Potti, A., Moazzam, N., Tendulkar, K., Javed, N.A., Koch, M. and Kargas, S. ( 2003) Immunohistochemical determination of vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. Anticancer Res23: 4023-4026.
57.
Quirt, I., Bodurth, A., Lohmann, R., Rusthoven, J., Belanger, K., Young, V. et al. (2002) Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs20: 431-437.
58.
Rini, B., Scjiller, J., Fruehauf, J., Cohen, E., Tarazi, J., Rosbrook, B. et al. (2008) Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736). J Clin Oncol26: Abstract 3543.
59.
Robert, C., Lazar, V., Lacroix, L., Farace, F., Lassau, N., Dromain, C. et al. (2009) Phase I/II study of the association of sorafenib and temozolimde (extended schedule) in patients with metastatic melanoma: A new clinical response profile with massive tumor necroses. J Clin Oncol27: Abstract 9062.
60.
Roy, R., Yang, J. and Moses, M.A.(2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol27: 5287-5296.
61.
Schadendorf, D., Algarra, S.M., Bastholt, L., Cinat, G., Dreno, B., Eggermont, A.M. et al. (2009) Immunotherapy of distant metastatic disease . Ann Oncol20(Suppl 6): vi41-50.
62.
Semenza, G.L. ( 2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today12: 853-859.
63.
Si, L., Chi, X., Yuan, C., Cui, X., Sheng, Y., Zhu, Y. et al. (2009) Durable response of the triple combination of temozolomide, sorafenib and bevacizumab as second-line therapy for patients with stage IV acral melanoma. J Clin Oncol27: Abstract e20010.
64.
Simonetti, O., Lucarini, G., Brancorsini, D., Nita, P., Bernardini, M.L., Biagini, G. et al. (2002) Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer95: 1963-1970.
65.
Spratlin, J.L., Cohen, R., Eadens, M., Gore, L., Camidge, R., Diab, S. et al. (2010) Phase 1 pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monocolonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol28: 780-786.
66.
Streit, M. and Detmar, M. ( 2003) Angiogenesis, lymphangiogenesis, and melanoma metastasis . Oncogene22: 3172-3179.
67.
Tarhini, A., Christensen, S., Frankel, P., Margolin, K., Ruel, C., Shipe-Spotloe, J. et al. (2009) Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin. J Clin Oncol27: Abstract 9028.
68.
Tentori, L., Dorio, A.S., Muzi, A., Lacal, P.M., Ruffini, F., Navarra, P. et al. (2008) The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep19: 1039-1043.
69.
Trikha, M., Zhou, Z., Nemeth, J.A., Chen, Q., Sharp, C., Emmell, E. et al. (2004) CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer110: 326-335.
70.
Ugurel, S., Rappl, G., Tilgen, W. and Reinhold, U. ( 2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival . J Clin Oncol19: 577-583.
71.
Varker, K.A., Biber, J.E., Kefauver, C., Jensen, R., Lehman, A., Young, D. et al. (2007) A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma . Ann Surg Oncol14: 2367-2376.
72.
Wedge, S.R., Ogilvie, D.J., Dukes, M., Kendrew, J., Chester, R., Jackson, J.A. et al. (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration . Cancer Res62: 4645-4655.
73.
Wheatley, K., Ives, N., Eggermont, J., Kirkwood, N., Cascinelli, S., Markovic, S.N. et al. (2007) Interferonalfa as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol25: Abstract 8526.
74.
Wolmark, N., Yothers, G., O’Connell, M.J., Sharif, S., Atkins, J.N., Seay, T.E. et al. (2009) A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol27: Abstract LBA4.
75.
Wyman, K., Spigel, D., Puzanov, I., Hainswroth, J., Kelley, P., Krozely, D. et al. (2007) A multicentre phase II study of erlotinib and bevacizumab in patients with metastatic melanoma. J Clin Oncol25: Abstract 8539.
